Lento Bio was formed in Upstate New York in 2022 as part of the Ichor Life Sciences umbrella, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by directly targeting macromolecular damage. Our approach is via rational, hypothesis-driven optimization of small molecule therapeutics done in collaboration with our academic partners. Our current primary focus is on developing our lead asset targeted at reducing damage to the lens and restoring accommodation in presbyopia, while also conducting research into systemic diseases characterized by similar damage modalities for future indication expansion.